William Lewis Sells 18,750 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of Insmed stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

William Lewis also recently made the following trade(s):

• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total transaction of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.84, for a total transaction of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Price Performance

Insmed stock traded down $0.22 during trading hours on Thursday, hitting $83.61. 2,291,313 shares of the stock were exchanged, compared to its average volume of 1,925,492. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $14.96 billion, a P/E ratio of -15.06 and a beta of 1.11. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.28. The business’s 50-day moving average is $73.87 and its two-hundred day moving average is $73.45.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Equities research analysts expect that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Institutional Trading of Insmed

Large investors have recently added to or reduced their stakes in the company. Jennison Associates LLC grew its stake in Insmed by 0.6% during the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after buying an additional 4,560 shares during the last quarter. Capital CS Group LLC bought a new stake in shares of Insmed during the fourth quarter valued at approximately $586,000. Orion Portfolio Solutions LLC grew its stake in shares of Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC grew its stake in shares of Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after purchasing an additional 21,833 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new stake in shares of Insmed during the third quarter valued at approximately $35,322,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on INSM shares. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Truist Financial reaffirmed a “buy” rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Stifel Nicolaus upped their price objective on shares of Insmed from $88.00 to $97.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research report on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $90.86.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.